Develops human monoclonal antibody therapeutics for cancer and other diseases. Markets DARZALEX for multiple myeloma and AL amyloidosis. Now — the numbers.
This is an established company with proven profits.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture.
The gap is $3.7B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 20.7× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 64% of them.
Analysts' average target sits 18% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 26% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales fell about 18% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The growth engine is running at low revs right now. Report-card grade: 2/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 39/100.
On our five-subject report card, GMAB sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GMAB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
Not covered, because the filings we hold do not carry it: the revenue breakdown.